 SIOUX FALLS, S.D.--BUSINESS WIRE--SAB Biotherapeutics SAB, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, July 13 at 5:00 p.m. ET. On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition C 